Cullinan Therapeutics (CGEM) Competitors $7.61 -0.32 (-4.04%) Closing price 04:00 PM EasternExtended Trading$7.60 0.00 (-0.07%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGEM vs. BEAM, DYN, APGE, TWST, TVTX, BHVN, IMCR, CDTX, AUPH, and WVEShould you be buying Cullinan Therapeutics stock or one of its competitors? The main competitors of Cullinan Therapeutics include Beam Therapeutics (BEAM), Dyne Therapeutics (DYN), Apogee Therapeutics (APGE), Twist Bioscience (TWST), Travere Therapeutics (TVTX), Biohaven (BHVN), Immunocore (IMCR), Cidara Therapeutics (CDTX), Aurinia Pharmaceuticals (AUPH), and WAVE Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry. Cullinan Therapeutics vs. Its Competitors Beam Therapeutics Dyne Therapeutics Apogee Therapeutics Twist Bioscience Travere Therapeutics Biohaven Immunocore Cidara Therapeutics Aurinia Pharmaceuticals WAVE Life Sciences Beam Therapeutics (NASDAQ:BEAM) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment. Is BEAM or CGEM more profitable? Cullinan Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -661.31%. Cullinan Therapeutics' return on equity of -36.56% beat Beam Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Beam Therapeutics-661.31% -43.15% -31.06% Cullinan Therapeutics N/A -36.56%-34.82% Which has more risk & volatility, BEAM or CGEM? Beam Therapeutics has a beta of 2.22, indicating that its stock price is 122% more volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.08, indicating that its stock price is 108% less volatile than the S&P 500. Do analysts prefer BEAM or CGEM? Beam Therapeutics presently has a consensus price target of $48.45, suggesting a potential upside of 187.56%. Cullinan Therapeutics has a consensus price target of $26.80, suggesting a potential upside of 252.17%. Given Cullinan Therapeutics' higher probable upside, analysts clearly believe Cullinan Therapeutics is more favorable than Beam Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 3 Strong Buy rating(s) 3.07Cullinan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of BEAM or CGEM? 99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 3.5% of Beam Therapeutics shares are held by company insiders. Comparatively, 7.2% of Cullinan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has better earnings and valuation, BEAM or CGEM? Cullinan Therapeutics has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeam Therapeutics$63.52M26.83-$376.74M-$4.50-3.74Cullinan TherapeuticsN/AN/A-$167.38M-$3.23-2.36 Does the media refer more to BEAM or CGEM? In the previous week, Cullinan Therapeutics had 9 more articles in the media than Beam Therapeutics. MarketBeat recorded 14 mentions for Cullinan Therapeutics and 5 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 1.04 beat Cullinan Therapeutics' score of 1.04 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryBeam Therapeutics and Cullinan Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Cullinan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CGEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGEM vs. The Competition Export to ExcelMetricCullinan TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$449.52M$3.06B$5.76B$9.84BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-2.3621.2231.3126.60Price / SalesN/A390.30461.30121.37Price / CashN/A44.4437.7659.36Price / Book0.918.0710.026.67Net Income-$167.38M-$54.08M$3.27B$265.59M7 Day Performance-0.78%2.26%3.17%3.42%1 Month Performance-7.53%3.42%4.34%1.09%1 Year Performance-59.30%18.61%44.11%23.85% Cullinan Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGEMCullinan Therapeutics1.7555 of 5 stars$7.61-4.0%$26.80+252.2%-58.0%$449.52MN/A-2.3630Analyst RevisionBEAMBeam Therapeutics2.04 of 5 stars$17.10-4.0%$48.45+183.4%-35.9%$1.80B$63.52M-3.80510Positive NewsDYNDyne Therapeutics3.5762 of 5 stars$12.33-0.4%$33.80+174.1%-69.0%$1.76BN/A-3.19100Positive NewsAnalyst UpgradeAPGEApogee Therapeutics3.7676 of 5 stars$36.90-1.0%$99.00+168.3%-20.5%$1.72BN/A-8.9391Positive NewsAnalyst ForecastTWSTTwist Bioscience3.9416 of 5 stars$28.02-0.4%$49.40+76.3%-39.7%$1.70B$312.97M-19.32990Positive NewsTVTXTravere Therapeutics2.3489 of 5 stars$18.77-0.3%$32.21+71.6%+92.5%$1.68B$233.18M-9.20460Positive NewsAnalyst ForecastGap UpBHVNBiohaven3.802 of 5 stars$16.02+2.0%$53.75+235.5%-62.3%$1.66BN/A-2.09239IMCRImmunocore1.5813 of 5 stars$32.31-1.7%$58.00+79.5%-9.7%$1.66B$310.20M-80.78320Positive NewsAnalyst ForecastCDTXCidara Therapeutics3.6357 of 5 stars$63.24-3.0%$64.14+1.4%+404.2%$1.65B$1.27M-5.6890Positive NewsAUPHAurinia Pharmaceuticals2.9997 of 5 stars$12.22-0.4%$12.00-1.8%+79.9%$1.62B$260.11M28.42300Positive NewsWVEWAVE Life Sciences4.7744 of 5 stars$9.74-0.2%$20.27+108.1%+78.4%$1.55B$108.30M-10.82240Insider Trade Related Companies and Tools Related Companies BEAM Alternatives DYN Alternatives APGE Alternatives TWST Alternatives TVTX Alternatives BHVN Alternatives IMCR Alternatives CDTX Alternatives AUPH Alternatives WVE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGEM) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access